RGC vs. XLV

Last updated Apr 2, 2026

Compare and contrast key facts about Regencell Bioscience Holdings Limited (RGC) and State Street Health Care Select Sector SPDR ETF (XLV).

XLV is a passively managed fund by State Street that tracks the performance of the Health Care Select Sector Index. It was launched on Dec 16, 1998.

Performance

RGC vs. XLV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Regencell Bioscience Holdings Limited (RGC) and State Street Health Care Select Sector SPDR ETF (XLV). The values are adjusted to include any dividend payments, if applicable.

RGC vs. XLV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RGC Regencell Bioscience Holdings Limited	60.57%	16,053.85%	-52.95%	-62.35%	-12.43%	203.33%
XLV State Street Health Care Select Sector SPDR ETF	-4.18%	14.50%	2.47%	2.07%	-2.08%	10.35%

Returns By Period

In the year-to-date period, RGC achieves a 60.57% return, which is significantly higher than XLV's -4.18% return.

RGC

• 1D: 32.60%
• 1M: 29.20%
• YTD: 60.57%
• 6M: 113.01%
• 1Y: 4,320.01%
• 3Y*: 267.20%
• 5Y*: —
• 10Y*: —

XLV

• 1D: 0.76%
• 1M: -6.43%
• YTD: -4.18%
• 6M: 3.83%
• 1Y: 4.90%
• 3Y*: 6.25%
• 5Y*: 6.59%
• 10Y*: 9.80%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RGC vs. XLV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RGC

RGC Risk / Return Rank: 100
RGC Sharpe Ratio Rank: 100
RGC Sortino Ratio Rank: 99
RGC Omega Ratio Rank: 99
RGC Calmar Ratio Rank: 100
RGC Martin Ratio Rank: 100

XLV

XLV Risk / Return Rank: 18
XLV Sharpe Ratio Rank: 19
XLV Sortino Ratio Rank: 18
XLV Omega Ratio Rank: 18
XLV Calmar Ratio Rank: 17
XLV Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RGC vs. XLV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Regencell Bioscience Holdings Limited (RGC) and State Street Health Care Select Sector SPDR ETF (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RGC	XLV	Difference
Sharpe ratio Return per unit of total volatility	11.42	0.28	+11.14
Sortino ratio Return per unit of downside risk	7.06	0.51	+6.55
Omega ratio Gain probability vs. loss probability	1.90	1.06	+0.83
Calmar ratio Return relative to maximum drawdown	45.20	0.28	+44.92
Martin ratio Return relative to average drawdown	58.42	0.58	+57.83
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RGC vs. XLV - Sharpe Ratio Comparison

The current RGC Sharpe Ratio is 11.42, which is higher than the XLV Sharpe Ratio of 0.28. The chart below compares the historical Sharpe Ratios of RGC and XLV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RGC	XLV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	11.42	0.28	+11.14
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.45	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.59	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.57	0.46	+0.11

Correlation

The correlation between RGC and XLV is 0.04, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RGC vs. XLV - Dividend Comparison

RGC has not paid dividends to shareholders, while XLV's dividend yield for the trailing twelve months is around 1.70%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
RGC Regencell Bioscience Holdings Limited	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XLV State Street Health Care Select Sector SPDR ETF	1.70%	1.60%	1.67%	1.59%	1.47%	1.33%	1.49%	2.17%	1.57%	1.47%	1.60%	1.43%

Drawdowns

RGC vs. XLV - Drawdown Comparison

The maximum RGC drawdown since its inception was -93.09%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for RGC and XLV.

Drawdown Indicators

	RGC	XLV	Difference
Max Drawdown Largest peak-to-trough decline	-93.09%	-39.17%	-53.92%
Max Drawdown (1Y) Largest decline over 1 year	-86.72%	-10.76%	-75.96%
Max Drawdown (5Y) Largest decline over 5 years	—	-17.11%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-28.40%	—
Current Drawdown Current decline from peak	-56.77%	-7.41%	-49.36%
Average Drawdown Average peak-to-trough decline	-59.11%	-7.12%	-51.99%
Ulcer Index Depth and duration of drawdowns from previous peaks	67.09%	5.11%	+61.98%

Volatility

RGC vs. XLV - Volatility Comparison

Regencell Bioscience Holdings Limited (RGC) has a higher volatility of 39.07% compared to State Street Health Care Select Sector SPDR ETF (XLV) at 4.79%. This indicates that RGC's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RGC	XLV	Difference
Volatility (1M) Calculated over the trailing 1-month period	39.07%	4.79%	+34.28%
Volatility (6M) Calculated over the trailing 6-month period	111.72%	10.29%	+101.43%
Volatility (1Y) Calculated over the trailing 1-year period	384.36%	17.73%	+366.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	314.10%	14.56%	+299.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	314.10%	16.53%	+297.57%